BioAtla (BCAB) Short Interest Ratio & Short Volume → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free BCAB Stock Alerts $3.13 +0.04 (+1.29%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media BioAtla Short Interest DataCurrent Short Volume5,420,000 sharesPrevious Short Volume5,590,000 sharesChange Vs. Previous Month-3.04%Dollar Volume Sold Short$15.50 millionShort Interest Ratio / Days to Cover10.1Last Record DateApril 15, 2024Outstanding Shares48,100,000 sharesPercentage of Shares Shorted11.27%Today's Trading Volume564,841 sharesAverage Trading Volume557,031 sharesToday's Volume Vs. Average101% Short Selling BioAtla ? Sign up to receive the latest short interest report for BioAtla and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBCAB Short Interest Over TimeBCAB Days to Cover Over TimeBCAB Percentage of Float Shorted Over Time Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. BioAtla Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20245,420,000 shares $15.50 million -3.0%N/A10.1 $2.86 3/31/20245,590,000 shares $19.23 million +9.0%N/A10.9 $3.44 3/15/20245,130,000 shares $12.52 million +0.4%N/A11.6 $2.44 2/29/20245,110,000 shares $13.80 million +1.4%N/A11 $2.70 2/15/20245,040,000 shares $13.36 million +6.6%N/A9.6 $2.65 1/31/20244,730,000 shares $9.06 million -3.3%N/A9.5 $1.92 Get the Latest News and Ratings for BCAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. 1/15/20244,890,000 shares $11.78 million +4.7%N/A9.5 $2.41 12/31/20234,670,000 shares $11.49 million +4.7%N/A9.5 $2.46 12/15/20234,460,000 shares $9.41 million +0.2%N/A9.6 $2.11 11/30/20234,450,000 shares $7.88 million +8.0%N/A10.9 $1.77 11/15/20234,120,000 shares $6.63 million +1.0%N/A12.1 $1.61 10/31/20234,080,000 shares $6.00 million -7.3%N/A13.9 $1.47 10/15/20234,400,000 shares $7.26 million -5.2%N/A17.5 $1.65 9/30/20234,640,000 shares $7.89 million -6.8%N/A20.1 $1.70 9/15/20234,980,000 shares $10.36 million +2.1%N/A20.7 $2.08 8/31/20234,880,000 shares $12.25 million +3.2%N/A13.6 $2.51 8/15/20234,730,000 shares $12.91 million +1.9%N/A12.1 $2.73 7/31/20234,640,000 shares $13.87 million -1.1%N/A11.1 $2.99 7/15/20234,690,000 shares $12.66 million +1.5%N/A10.7 $2.70 6/30/20234,620,000 shares $13.86 million +25.9%N/A8.7 $3.00 6/15/20233,670,000 shares $13.73 million +1.7%N/A6.1 $3.74 5/31/20233,610,000 shares $11.37 million +0.6%N/A7.3 $3.15 5/15/20233,590,000 shares $13.89 million -5.0%N/A7.2 $3.87 4/30/20233,780,000 shares $12.74 million +16.7%N/A7.4 $3.37 4/15/20233,240,000 shares $11.66 million -10.3%N/A5.7 $3.60 3/31/20233,610,000 shares $9.67 million +10.4%N/A4.5 $2.68 3/15/20233,270,000 shares $8.37 million -0.6%N/A4.6 $2.56 2/28/20233,290,000 shares $9.80 million +13.8%N/A4.8 $2.98 2/15/20232,890,000 shares $9.88 million -0.3%N/A4.3 $3.42 1/31/20232,900,000 shares $10.99 million -10.8%N/A3.3 $3.79 1/15/20233,250,000 shares $11.25 million -21.9%N/A3.7 $3.46 12/30/20224,160,000 shares $34.32 million +2.2%N/A6.4 $8.25 12/15/20224,070,000 shares $36.51 million -5.1%N/A7.5 $8.97 11/30/20224,290,000 shares $47.23 million -3.6%N/A7.7 $11.01 11/15/20224,450,000 shares $39.16 million +10.2%N/A8 $8.80 10/31/20224,040,000 shares $27.84 million -20.6%N/A3.5 $6.89 10/15/20225,090,000 shares $35.07 million -1.0%N/A5.4 $6.89 9/30/20225,140,000 shares $39.58 million +27.5%N/A5.2 $7.70 9/15/20224,030,000 shares $34.46 million +7.8%N/A3.7 $8.55 8/31/20223,740,000 shares $32.58 million -32.9%N/A3.6 $8.71Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. BCAB Short Interest - Frequently Asked Questions What is BioAtla's current short interest? Short interest is the volume of BioAtla shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 5,420,000 shares of BCAB short. Learn More on BioAtla's current short interest. What is a good short interest ratio for BioAtla? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCAB shares currently have a short interest ratio of 10.0. Learn More on BioAtla's short interest ratio. Which institutional investors are shorting BioAtla? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioAtla: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is BioAtla's short interest increasing or decreasing? BioAtla saw a drop in short interest in April. As of April 15th, there was short interest totaling 5,420,000 shares, a drop of 3.0% from the previous total of 5,590,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does BioAtla's short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to BioAtla: Cardiff Oncology, Inc. (8.92%), Scilex Holding (7.13%), Cardiol Therapeutics Inc. (0.42%), Molecular Partners AG (0.16%), Vaxart, Inc. (10.37%), DBV Technologies S.A. (0.27%), Cellectis S.A. (1.21%), Genfit S.A. (0.19%), Vigil Neuroscience, Inc. (6.18%), Omega Therapeutics, Inc. (21.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short BioAtla stock? Short selling BCAB is an investing strategy that aims to generate trading profit from BioAtla as its price is falling. BCAB shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioAtla? A short squeeze for BioAtla occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCAB, which in turn drives the price of the stock up even further. How often is BioAtla's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCAB, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Cardiff Oncology Short Interest Scilex Short Interest Cardiol Therapeutics Short Interest Molecular Partners Short Interest Vaxart Short Interest DBV Technologies Short Interest Cellectis Short Interest Genfit Short Interest Vigil Neuroscience Short Interest Omega Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BCAB) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithHow Biden has already won 2024Porter & CompanyThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders“Crash Insurance” For Your RetirementUnstoppable ProsperityThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing